Nexstim

9.40 EUR

+2.06 %

5,646 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+2.06 %
+3.98 %
-25.98 %
-33.80 %
-37.12 %
+22.08 %
+150.67 %
+59.32 %
-98.45 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
68.01M EUR
Turnover
31.15K EUR
P/E (adj.) (26e)
66.98
EV/EBIT (adj.) (26e)
58.25
P/B (26e)
12.98
EV/S (26e)
5.53
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.50 EUR
Updated
2026-02-26
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-02-27

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Viime aikoina useampi kaveri on laittanut huolestuneena viestiä että pitäisikö Nexstimin osakkeet nyt myydä kun kurssi on laskenut niin paljon. Halusin koota yhteen oman kattavan näkemykseni siitä, miksi Nexstim on edelleen ehdottomasti pidemmän tähtäimen omistus. Samalla haluan ...
5/6/2026, 12:18 PM
by Kyhnykeisari
83
And here is this morning’s Nexstim article; the technology is certainly appreciated: The Europe Times | European Business News for Global Readers Nexstim Breaks New Ground and Makes the Impossible Possible in Medical... Nexstim, a Finnish medical technology company, is advancing ...
yesterday
by AccionHombre
33
Good catch! The topic of the presentation in the background seems to be the necessity of nTMS for BCI implantation. One might assume that the matter would be expressed that way on Brainlab’s slides, but the TUM Klinikum logo is visible in the top right corner.
5/7/2026, 5:36 AM
by Kyhnykeisari
21
An absolutely fantastic summary, “kyhnykeisari”. One of the best I have ever read on these forums. A BIG THANK YOU. I appreciate it.
5/6/2026, 2:25 PM
by Taitoo
17
Good summary, thanks @Kyhnykeisari . It’s always good to compile these every now and then. Personally, I’m invested because of point 5 and will re-evaluate the situation after the first published results.
5/6/2026, 1:17 PM
by AccionHombre
15
Thanks for the excellent summary. One natural partner for the BCI application would likely be TUM in Munich, which aims to be the leading star of brain-computer interfaces in Europe by 2030: “By 2030, we aim to establish the leading European hub for brain-computer interfaces - in...
5/6/2026, 6:53 PM
14
Fortunately, some digging reveals an article on Sinaptica’s progress. They raised 9M in an oversubscribed last round and are now heading towards new patient trials starting later this year. The folks at Sinaptica seem very confident, which of course suits us well. They have 5 treatment...
5/5/2026, 6:56 AM
by AccionHombre
11
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.